Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

Pfizer (NYSE:PFE | PFE Price Prediction) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at ...

A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer's acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth. Click here to read why I rate ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...